secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celcuity Inc. (CELC)
CIK:        0001603454
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001493152-26-006444
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celcuity appoints Charles Romp to board of directors; brings commercial oncology expertise
--------------------------------------------------------------------------------

- Charles (Chip) R. Romp appointed to board, effective Feb 11, 2026; board size increased from 7 to 8.
- Romp is CEO of Secura Bio, previously EVP Commercial at Seagen (sold to Pfizer), with 25+ years oncology experience.
- He will receive $50k annual cash retainer, $100k annual equity award, and pro-rated grant of 215 restricted shares vesting by 2026 annual meeting or April 30.
- Company notes preparation for potential approval and launch of gedatolisib later this year (HR+/HER2- advanced breast cancer).
- Romp qualifies as independent under Nasdaq and SEC rules; no committee assignments yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603454/000149315226006444/0001493152-26-006444-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603454/000149315226006444/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-006444

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer